<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0905245266
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZOLEDRONIC ACID FRESENIUS KABI 4 MG/5 ML CONC. FOR SOLUTION FOR INFUSION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ZOLEDRONIC ACID
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.8
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        78.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="FRESENIUS KABI" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            FRESENIUS KABI
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 606]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALHAYA MEDICAL CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            FRESENIUS KABI
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M05BA08 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
            <div class="p-20 text-center font-20">
                <div class="p-10 bg-red"><i class="fa fa-times-circle"></i>&nbsp;&#x644;&#x645; &#x64A;&#x62A;&#x645; &#x625;&#x62F;&#x62E;&#x627;&#x644; &#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A;  &#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x644;&#x647;&#x630;&#x627; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621; &#x62D;&#x62A;&#x649; &#x627;&#x644;&#x622;&#x646;</div>
            </div>
    </div>
    <div id="A-div" class="box-data">
            <div class="p-20 text-center font-20">
                <span class="p-10 bg-red"><i class="fa fa-times-circle"></i>&nbsp;&#x644;&#x645; &#x64A;&#x62A;&#x645; &#x625;&#x62F;&#x62E;&#x627;&#x644; &#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A;  &#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x644;&#x647;&#x630;&#x627; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621; &#x62D;&#x62A;&#x649; &#x627;&#x644;&#x622;&#x646;</span>
            </div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zoledronic acid Fresenius Kabi 4 mg/5 ml concentrate for solution for infusion

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One vial with 5 ml concentrate contains 4 mg of zoledronic acid (as monohydrate).
One ml concentrate contains 0.8 mg of zoledronic acid (as monohydrate)
For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for
solution for infusion (sterile concentrate)
Clear and colourless solution

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>- Prevention of skeletal related events (pathological fractures, spinal compression, radiation or<br />surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced<br />malignancies involving bone.<br />- Treatment of adult patients with tumour-induced hypercalcaemia (TIH).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0cm; margin-right:25.2pt">Zoledronic acid Fresenius Kabi must only be prescribed and administered to patients by healthcare professionals experienced in the administration of intravenous bisphosphonates.</p><p><u>Posology </u></p><p><em><u>Prevention of skeletal related events in patients with advanced malignancies involving bone</u></em></p><p><em>Adults and elderly</em></p><p>The recommended dose in the prevention of skeletal related events in patients with advanced</p><p>malignancies involving bone is 4 mg zoledronic acid every 3 to 4 weeks.</p><p style="margin-left:0cm; margin-right:14.4pt">Patients should also be administered an oral calcium supplement of 500 mg and 400 IU vitamin D daily.</p><p style="margin-left:0cm; margin-right:3.6pt"><!--[if gte vml 1]><v:shapetype id="_x0000_t202"
 coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="_x005f_x0000_s0" o:spid="_x0000_s1026" type="#_x0000_t202"
 style='position:absolute;margin-left:518.8pt;margin-top:772.75pt;width:7.35pt;
 height:10.9pt;z-index:-251673088;mso-wrap-distance-left:0;
 mso-wrap-distance-right:0;mso-position-horizontal-relative:page;
 mso-position-vertical-relative:page' filled="f" stroked="f">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='margin-top:.55pt;line-height:10.05pt;mso-line-height-rule:
    exactly;vertical-align:baseline'><span style='font-size:9.5pt;mso-bidi-font-size:
    11.0pt;mso-fareast-font-family:"Times New Roman";color:black'>1<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="square" anchorx="page" anchory="page"/>
</v:shape><![endif]--><!--[if !vml]--><img src="file:///C:/Users/test/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" alt="Text Box: 1" width="14" height="19" /><!--[endif]-->The decision to treat patients with bone metastases for the prevention of skeletal related events should consider that the onset of treatment effect is 2-3 months.</p><p>&nbsp;</p><p style="margin-left:3.6pt; margin-right:0cm"><em><u>Treatment of TIH</u></em></p><p style="margin-left:3.6pt"><em>Adults and elderly</em></p><p style="margin-left:3.6pt">The recommended dose in hypercalcaemia (albumin-corrected serum calcium &ge; 12.0 mg/dl or 3.0</p><p style="margin-left:3.6pt; margin-right:0cm">mmol/l) is a single dose of 4 mg zoledronic acid.</p><p style="margin-left:3.6pt; margin-right:0cm"><em>Renal impairment<br />TIH:</em></p><p style="margin-left:3.6pt; margin-right:28.8pt">Zoledronic acid Fresenius Kabi treatment in TIH patients who also have severe renal impairment should be considered only after evaluating the risks and benefits of treatment. In the clinical studies, patients with serum creatinine &gt; 400 &mu;mol/l or &gt; 4.5 mg/dl were excluded. No dose adjustment is necessary in TIH patients with serum creatinine &lt; 400 &mu;mol/l or &lt; 4.5 mg/dl (see section 4.4).</p><p style="margin-left:3.6pt; margin-right:14.4pt"><em>Prevention of skeletal related events in patients with advanced malignancies involving bone: </em>When initiating treatment with Zoledronic acid Fresenius Kabi in patients with multiple myeloma or metastatic bone lesions from solid tumours, serum creatinine and creatinine clearance (CLcr) should be determined. CLcr is calculated from serum creatinine using the Cockcroft-Gault formula. Zoledronic acid Fresenius Kabi is not recommended for patients presenting with severe renal impairment prior to initiation of therapy, which is defined for this population as CLcr &lt; 30 ml/min. In clinical trials with Zoledronic acid, patients with serum creatinine &gt; 265 &mu;mol/l or &gt; 3.0 mg/dl were excluded.</p><p style="margin-left:3.6pt; margin-right:10.8pt">In patients with bone metastases presenting with mild to moderate renal impairment prior to initiation of therapy, which is defined for this population as CLcr 30&ndash;60 ml/min, the following Zoledronic acid Fresenius Kabi dose is recommended (see also section 4.4):</p><p style="margin-left:25.2pt; margin-right:0cm"><strong>Baseline Creatinine Clearance (ml/min)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Zoledronic acid Fresenius Kabi Recommended</strong></p><p style="margin-left:327.6pt"><strong>Dose *</strong></p><p style="margin-left:100.8pt; margin-right:0cm"><!--[if gte vml 1]><v:line
 id="_x0000_s1027" style='position:absolute;left:0;text-align:left;z-index:251658752;
 mso-position-horizontal-relative:page;mso-position-vertical-relative:page'
 from="65.5pt,455.5pt" to="528.75pt,455.5pt" strokeweight="1.2pt">
 <w:wrap anchorx="page" anchory="page"/>
</v:line><![endif]--><!--[if !vml]--><img src="file:///C:/Users/test/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" width="620" height="2" /><!--[endif]-->&gt; 60&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.0 mg zoledronic acid</p><p style="margin-left:100.8pt; margin-right:0cm">50&ndash;60&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3.5 mg* zoledronic acid</p><p style="margin-left:100.8pt; margin-right:0cm">40&ndash;49&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3.3 mg* zoledronic acid</p><p style="margin-left:100.8pt; margin-right:0cm"><u>30&ndash;39&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3.0 mg* zoledronic acid</u></p><p style="margin-left:3.6pt; margin-right:18.0pt"><!--[if gte vml 1]><v:line id="_x0000_s1028"
 style='position:absolute;left:0;text-align:left;z-index:251659776;
 mso-position-horizontal-relative:page;mso-position-vertical-relative:page'
 from="65.5pt,508.1pt" to="529pt,508.1pt" strokeweight=".7pt">
 <w:wrap anchorx="page" anchory="page"/>
</v:line><![endif]--><!--[if !vml]--><img src="file:///C:/Users/test/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" width="620" height="2" /><!--[endif]-->* Doses have been calculated assuming target AUC of 0.66 (mg&middot;hr/l) (CLcr=75 ml/min). The reduced doses for patients with renal impairment are expected to achieve the same AUC as that seen in patients with creatinine clearance of 75 ml/min.</p><p style="margin-left:3.6pt; margin-right:18.0pt">Following initiation of therapy, serum creatinine should be measured prior to each dose of Zoledronic acid and treatment should be withheld if renal function has deteriorated. In the clinical trials, renal deterioration was defined as follows:</p><p style="margin-left:25.2pt; margin-right:14.4pt; text-indent:-21.6pt">-&nbsp;&nbsp;&nbsp;&nbsp; For patients with normal baseline serum creatinine (&lt; 1.4 mg/dl or &lt; 124 &mu;mol/l), an increase of 0.5 mg/dl or 44 &mu;mol/l;</p><p style="margin-left:25.2pt; margin-right:18.0pt; text-align:justify; text-indent:-21.6pt">-&nbsp;&nbsp;&nbsp;&nbsp; For patients with an abnormal baseline creatinine (&gt; 1.4 mg/dl or &gt; 124 &mu;mol/l), an increase of 1.0 mg/dl or 88 &mu;mol/l.</p><p style="margin-left:3.6pt; margin-right:7.2pt; text-align:justify">In the clinical studies, Zoledronic acid treatment was resumed only when the creatinine level returned to within 10% of the baseline value (see section 4.4). Zoledronic acid Fresenius Kabi treatment should be resumed at the same dose as that given prior to treatment interruption.</p><p>&nbsp;</p><p>2</p><p>&nbsp;</p><p style="margin-left:7.2pt; margin-right:0cm"><em>Paediatric population</em></p><p style="margin-left:7.2pt; margin-right:21.6pt">The safety and efficacy of zoledronic acid in children aged 1 year to 17 years have not been established. Currently available data are described in sections 4.4 and 5.1 but no recommendation on a posology can be made.</p><p style="margin-left:7.2pt; margin-right:0cm"><u>Method of administration</u></p><p style="margin-left:7.2pt; margin-right:0cm">Intravenous use.</p><p style="margin-left:7.2pt">Zoledronic acid Fresenius Kabi 4 mg/5 ml concentrate for solution for infusion, further diluted in 100</p><p style="margin-left:7.2pt; margin-right:0cm">ml (see section 6.6), should be given as a single intravenous infusion in no less than 15 minutes.</p><p style="margin-left:7.2pt; margin-right:25.2pt">In patients with mild to moderate renal impairment, reduced Zoledronic acid Fresenius Kabi doses are recommended (see section &ldquo;Posology&rdquo; above and section 4.4.).</p><p style="margin-left:7.2pt; margin-right:0cm"><u>Instructions for preparing reduced doses of Zoledronic acid Fresenius Kabi </u><br />Withdraw an appropriate volume of the concentrate needed, as follows:</p><p style="margin-left:7.2pt; margin-right:0cm">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.4 ml for 3.5 mg dose</p><p style="margin-left:7.2pt; margin-right:0cm">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.1 ml for 3.3 mg dose</p><p style="margin-left:7.2pt; margin-right:0cm">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3.8 ml for 3.0 mg dose</p><p style="margin-left:7.2pt; margin-right:18.0pt">The withdrawn amount of concentrate must be further diluted in 100 ml of sterile 0.9% w/v sodium chloride solution or 5% w/v glucose solution. The dose must be given as a single intravenous infusion over no less than 15 minutes.</p><p style="margin-left:7.2pt; margin-right:21.6pt">Zoledronic acid Fresenius Kabi concentrate must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer&rsquo;s solution, and should be administered as a single intravenous solution in a separate infusion line.</p><p style="margin-left:7.2pt; margin-right:36.0pt">Patients must be maintained well hydrated prior to and following administration of Zoledronic acid Fresenius Kabi.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance, to other bisphosphonates or to any of the excipients listed in section 6.1.
Breast-feeding (see section 4.6)

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:7.2pt; margin-right:0cm"><u>General </u>&nbsp;</p><p style="margin-left:7.2pt; margin-right:7.2pt">Patients must be assessed prior to administration of Zoledronic acid Fresenius Kabi to ensure that they are adequately hydrated.</p><p style="margin-left:7.2pt; margin-right:0cm">Overhydration should be avoided in patients at risk of cardiac failure.</p><p style="margin-left:7.2pt; margin-right:25.2pt"><!--[if gte vml 1]><v:shapetype id="_x0000_t202"
 coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
 left:0;text-align:left;margin-left:517.15pt;margin-top:772.3pt;width:10.4pt;
 height:11.45pt;z-index:-251672064;mso-wrap-distance-left:0;
 mso-wrap-distance-right:0;mso-position-horizontal-relative:page;
 mso-position-vertical-relative:page' filled="f" stroked="f">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='margin-top:.9pt;line-height:10.15pt;mso-line-height-rule:
    exactly;vertical-align:baseline'><span style='font-size:10.0pt;mso-bidi-font-size:
    11.0pt;mso-fareast-font-family:"Times New Roman";color:black'>3<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="square" anchorx="page" anchory="page"/>
</v:shape><![endif]--><!--[if !vml]--><img src="file:///C:/Users/test/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" alt="Text Box: 3" width="18" height="20" /><!--[endif]-->Standard hypercalcaemia-related metabolic parameters, such as serum levels of calcium, phosphate and magnesium, should be carefully monitored after initiating Zoledronic acid Fresenius Kabi therapy. If hypocalcaemia, hypophosphataemia, or hypomagnesaemia occurs, short-term supplemental therapy may be necessary. Untreated hypercalcaemia patients generally have some degree of renal function impairment, therefore careful renal function monitoring should be considered.</p><p>&nbsp;</p><p style="margin-left:10.8pt; margin-right:18.0pt">Other products containing zoledronic acid as active substances are available for osteoporosis indications and treatment of Paget&acute;s disease of the bone. Patients being treated with Zoledronic acid Fresenius Kabi should not be treated with any other medicines containing zoledronic acid or any other bisphosphonate concomitantly, since the combined effects of these agents are unknown.</p><p style="margin-left:10.8pt; margin-right:0cm"><u>Renal insufficiency</u></p><p style="margin-left:10.8pt; margin-right:18.0pt">Patients with TIH with evidence of deterioration in renal function should be appropriately evaluated with consideration given as to whether the potential benefit of treatment with Zoledronic acid Fresenius Kabi outweighs the possible risk.</p><p style="margin-left:10.8pt; margin-right:18.0pt">The decision to treat patients with bone metastases for the prevention of skeletal related events should consider that the onset of treatment effect is 2&ndash;3 months.</p><p style="margin-left:10.8pt; margin-right:10.8pt">Zoledronic acid, used as indicated in sections 4.1 and 4.2, has been associated with reports of renal dysfunction. Factors that may increase the potential for deterioration in renal function include dehydration, pre-existing renal impairment, multiple cycles of Zoledronic acid Fresenius Kabi and other bisphosphonates as well as use of other nephrotoxic medicinal products. While the risk is reduced with a dose of 4 mg zoledronic acid administered over 15 minutes, deterioration in renal function may still occur. Renal deterioration, progression to renal failure and dialysis have been reported in patients after the initial dose or a single dose of 4 mg zoledronic acid. Increases in serum creatinine also occur in some patients with chronic administration of zoledronic acid at recommended doses for prevention of skeletal related events, although less frequently.</p><p style="margin-left:10.8pt; margin-right:18.0pt">Patients should have their serum creatinine levels assessed prior to each dose of Zoledronic acid Fresenius Kabi. Upon initiation of treatment in patients with bone metastases with mild to moderate renal impairment, lower doses of Zoledronic acid Fresenius Kabi are recommended. In patients who show evidence of renal deterioration during treatment, Zoledronic acid Fresenius Kabi should be withheld. Zoledronic acid Fresenius Kabi should only be resumed when serum creatinine returns to within 10% of baseline.</p><p style="margin-left:10.8pt; margin-right:32.4pt">Zoledronic acid Fresenius Kabi treatment should be resumed at the same dose as that given prior to treatment interruption.</p><p style="margin-left:10.8pt; margin-right:10.8pt">In view of the potential impact of zoledronic acid, on renal function, the lack of clinical safety data in patients with severe renal impairment (in clinical trials defined as serum creatinine ? 400 &mu;mol/l or ? 4.5 mg/dl for patients with TIH and ? 265 &mu;mol/l or ? 3.0 mg/dl for patients with cancer and bone metastases, respectively) at baseline and only limited pharmacokinetic data in patients with severe renal impairment at baseline (creatinine clearance &lt; 30 ml/min), the use of Zoledronic acid Fresenius Kabi is not recommended in patients with severe renal impairment.</p><p style="margin-left:10.8pt; margin-right:0cm"><u>Hepatic insufficiency</u></p><p style="margin-left:10.8pt">As only limited clinical data are available in patients with severe hepatic insufficiency, no specific</p><p style="margin-left:10.8pt">recommendations can be given for this patient population.</p><p style="margin-left:10.8pt; margin-right:0cm"><u>Osteonecrosis of the jaw</u></p><p style="margin-left:3.6pt; margin-right:21.6pt"><!--[if gte vml 1]><v:shape id="_x0000_s1027"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:516.35pt;margin-top:772.75pt;width:12.3pt;height:10.9pt;z-index:-251671040;
 mso-wrap-distance-left:0;mso-wrap-distance-right:0;
 mso-position-horizontal-relative:page;mso-position-vertical-relative:page'
 filled="f" stroked="f">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='margin-top:.55pt;line-height:10.05pt;mso-line-height-rule:
    exactly;vertical-align:baseline'><span style='font-size:9.5pt;mso-bidi-font-size:
    11.0pt;mso-fareast-font-family:"Times New Roman";color:black'>4<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="square" anchorx="page" anchory="page"/>
</v:shape><![endif]--><!--[if !vml]--><img src="file:///C:/Users/test/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" alt="Text Box: 4" width="21" height="19" /><!--[endif]-->Osteonecrosis of the jaw (ONJ) has been reported in patients, predominantly those with cancer, receiving treatment with medicinal products that inhibit bone resorption, such as zoledronic acid. Many of these patients were also receiving chemotherapy and corticosteroids. The majority of reported cases have been associated with dental procedures such as tooth extraction. Many had signs of local infection including osteomyelitis.</p><p style="margin-left:3.6pt; margin-right:0cm">The following risk factors should be considered when evaluating an individual&rsquo;s risk of developing</p><p style="margin-left:3.6pt; margin-right:0cm">ONJ:</p><p style="margin-left:3.6pt">- Potency of the bisphosphonate (higher risk for highly potent compounds), route of administration</p><p style="margin-left:3.6pt">(higher risk for parenteral administration) and cumulative dose</p><p style="margin-left:3.6pt; margin-right:0cm">- Cancer, chemotherapy (see section 4.5), radiotherapy, corticosteroids, smoking</p><p style="margin-left:3.6pt; margin-right:0cm">- History of dental disease, poor oral hygiene, periodontal disease, invasive dental procedures and poorly</p><p style="margin-left:3.6pt">fitting dentures</p><p style="margin-left:3.6pt; margin-right:32.4pt">A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with concomitant risk factors.</p><p style="margin-left:3.6pt; margin-right:25.2pt">While on treatment, these patients should avoid invasive dental procedures if possible. For patients who develop osteonecrosis of the jaw while on bisphosphonate therapy, dental surgery may exacerbate the condition. For patients requiring dental procedures, there are no data available to suggest whether discontinuation of bisphosphonate treatment reduces the risk of osteonecrosis of the jaw. Clinical judgement of the treating physician should guide the management plan of each patient based on individual benefit/risk assessment.</p><p style="margin-left:3.6pt; margin-right:0cm"><u>Musculoskeletal pain</u></p><p style="margin-left:3.6pt; margin-right:14.4pt">In post-marketing experience, severe and occasionally incapacitating bone, joint, and/or muscle pain have been reported in patients that were given zoledronic acid as indicated in section 4.1. and 4.2. However, such reports have been infrequent. The time to onset of symptoms varied from one day to several months after starting treatment. Most patients had relief of symptoms after stopping treatment. A subset had recurrence of symptoms when rechallenged with the zoledronic acid or another bisphosphonate.</p><p style="margin-left:3.6pt; margin-right:0cm"><u>Atypical fractures of the femur</u></p><p style="margin-left:3.6pt; margin-right:14.4pt">Atypical subtrochanteric and diaphyseal femoral fractures have been reported with bisphosphonate therapy, primarily in patients receiving long-term treatment for osteoporosis. These transverse or short oblique fractures can occur anywhere along the femur from just below the lesser trochanter to just above the supracondylar flare. These fractures occur after minimal or no trauma and some patients experience thigh or groin pain, often associated with imaging features of stress fractures, weeks to months before presenting with a completed femoral fracture. Fractures are often bilateral; therefore the contralateral femur should be examined in bisphosphonate-treated patients who have sustained a femoral shaft fracture. Poor healing of these fractures has also been reported. Discontinuation of bisphosphonate therapy in patients suspected to have an atypical femur fracture should be considered pending evaluation of the patient, based on an individual benefit risk assessment.</p><p style="margin-left:3.6pt; margin-right:21.6pt">During bisphosphonate treatment patients should be advised to report any thigh, hip or groin pain and any patient presenting with such symptoms should be evaluated for an incomplete femur fracture.</p><p style="margin-left:3.6pt; margin-right:0cm">Hypocalcaemia</p><p style="margin-left:3.6pt; margin-right:14.4pt">Hypocalcaemia has been reported in patients treated with zoledronic acid. Cardiac arrhythmias and neurologic adverse events (including seizures, numbness and tetany) have been reported secondary to cases of severe hypocalcaemia. Cases of severe hypocalcaemia requiring hospitalisation have been reported. In some instances, the hypocalcaemia may be life-threatening (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:10.8pt; margin-right:10.8pt; text-align:justify">In clinical studies, zoledronic acid, used as indicated in section 4.1 and 4.2, has been administered concomitantly with commonly used anticancer agents, diuretics, antibiotics and analgesics without clinically apparent interactions occurring. Zoledronic acid shows no appreciable binding to plasma proteins and does not inhibit human P450 enzymes <em>in vitro </em>(see section 5.2), but no formal clinical interaction studies have been performed.</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t202" coordsize="21600,21600" o:spt="202"
 path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
 margin-left:516.7pt;margin-top:772.3pt;width:11.8pt;height:11.45pt;z-index:-251670016;
 mso-wrap-distance-left:0;mso-wrap-distance-right:0;
 mso-position-horizontal-relative:page;mso-position-vertical-relative:page'
 filled="f" stroked="f">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='margin-top:.9pt;line-height:10.15pt;mso-line-height-rule:
    exactly;vertical-align:baseline'><span style='font-size:10.0pt;mso-bidi-font-size:
    11.0pt;mso-fareast-font-family:"Times New Roman";color:black'>6<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="square" anchorx="page" anchory="page"/>
</v:shape><![endif]--><!--[if !vml]--><img src="file:///C:/Users/test/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" alt="Text Box: 6" width="20" height="19" /><!--[endif]-->Caution is advised when bisphosphonates are administered with aminoglycosides, since both agents may have an additive effect, resulting in a lower serum calcium level for longer periods than required</p><p style="margin-left:0cm; margin-right:10.8pt; text-align:justify">Caution is indicated when Zoledronic acid Fresenius Kabi is used with other potentially nephrotoxic medicinal products. Attention should also be paid to the possibility of hypomagnesaemia developing during treatment.</p><p style="margin-left:7.2pt; margin-right:36.0pt">In multiple myeloma patients, the risk of renal dysfunction may be increased when Zoledronic acid Fresenius Kabi is used in combination with thalidomide.</p><p>Caution is advised when Zoledronic acid is administered with anti-angiogenic medicinal products, as an increase in the incidence of ONJ has been observed in patients treated concomitantly with these medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:7.2pt; margin-right:0cm"><u>Pregnancy</u></p><p style="margin-left:7.2pt; margin-right:0cm">Pregnancy Category D</p><p style="margin-left:7.2pt; margin-right:18.0pt">There are no adequate data on the use of zoledronic acid in pregnant women. Animal reproduction studies with zoledronic acid have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. Zoledronic acid Fresenius Kabi should not be used during pregnancy.</p><p style="margin-left:7.2pt; margin-right:0cm"><u>Breast-feeding</u></p><p style="margin-left:7.2pt">It is not known whether zoledronic acid is excreted into human milk. Zoledronic acid Fresenius Kabi</p><p style="margin-left:7.2pt; margin-right:0cm">is contraindicated in breast-feeding women (see section 4.3).</p><p style="margin-left:7.2pt; margin-right:0cm"><u>Fertility</u></p><p style="margin-left:7.2pt; margin-right:28.8pt">Zoledronic acid was evaluated in rats for potential adverse effects on fertility of the parental and F1generation. This resulted in exaggerated pharmacological effects considered to be related to the compound&rsquo;s inhibition of skeletal calcium metabolisation, resulting in periparturient hypocalcaemia, a bisphosphonate class effect, dystocia and early termination of the study. Thus these results precluded determining a definitive effect of zoledronic acid on fertility in humans.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:7.2pt; margin-right:18.0pt">Adverse reactions, such as dizziness and somnolence, may have influence on the ability to drive or use machines, therefore caution should be exercised with the use of Zoledronic acid Fresenius Kabi along with driving and operating of machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:7.2pt; margin-right:0cm"><u>Summary of the safety profile</u></p><p style="margin-left:7.2pt; margin-right:18.0pt">Within three days after zoledronic acid administration, used as indicated in section 4.1. and 4.2., an acute phase reaction has commonly been reported, with symptoms including bone pain, fever, fatigue, arthralgia, myalgia and rigors; these symptoms usually resolve within a few days (see description of selected adverse reactions).</p><p style="margin-left:7.2pt; margin-right:18.0pt">The following are the important identified risks with Zoledronic acid in the approved indications: Renal function impairment, osteonecrosis of the jaw, acute phase reaction, hypocalcaemia, ocular adverse events, atrial fibrillation, anaphylaxis. The frequencies for each of these identified risks are</p><p style="text-align:right">7</p><p>&nbsp;</p><p>shown in Table 1.</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t202"
 coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
 margin-left:517.4pt;margin-top:772.75pt;width:10.4pt;height:10.9pt;z-index:-251668992;
 mso-wrap-distance-left:0;mso-wrap-distance-right:0;
 mso-position-horizontal-relative:page;mso-position-vertical-relative:page'
 filled="f" stroked="f">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='margin-top:.55pt;line-height:10.05pt;mso-line-height-rule:
    exactly;vertical-align:baseline'><span style='font-size:9.5pt;mso-bidi-font-size:
    11.0pt;mso-fareast-font-family:"Times New Roman";color:black'>8<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="square" anchorx="page" anchory="page"/>
</v:shape><![endif]--><!--[if !vml]--><img src="file:///C:/Users/test/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" alt="Text Box: 8" width="18" height="19" /><!--[endif]--><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p style="margin-left:10.8pt; margin-right:21.6pt">The following adverse reactions, listed in Table 1, have been accumulated from clinical studies and post-marketing reports following predominantly chronic treatment with 4 mg zoledronic acid:</p><p style="margin-left:10.8pt; margin-right:0cm"><strong>Table 1</strong></p><p style="margin-left:10.8pt; margin-right:10.8pt">Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common (21/10), common (21/100 to &lt;1/10), uncommon (21/1,000 to &lt;1/100), rare (21/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="border-color:black; height:54.0pt; vertical-align:top; width:429.85pt"><p style="margin-left:3.6pt"><strong><em>Blood and lymphatic system disorders</em></strong></p><p style="margin-left:82.8pt">Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaemia</p><p style="margin-left:82.8pt; margin-right:0cm">Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thrombocytopenia, leukopenia</p><p style="margin-left:82.8pt; margin-right:0cm">Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pancytopenia</p></td></tr><tr><td style="border-color:black; height:40.1pt; vertical-align:top; width:429.85pt"><p style="margin-left:3.6pt"><strong><em>Immune system disorders</em></strong></p><p style="margin-left:82.8pt">Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypersensitivity reaction</p><p style="margin-left:82.8pt; margin-right:0cm">Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Angioneurotic oedema</p></td></tr><tr><td style="border-color:black; height:41.25pt; vertical-align:top; width:429.85pt"><p style="margin-left:3.6pt"><strong><em>Psychiatric disorders</em></strong></p><p style="margin-left:82.8pt">Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anxiety, sleep disturbance</p><p style="margin-left:82.8pt; margin-right:0cm">Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Confusion</p></td></tr><tr><td style="border-color:black; height:101.3pt; vertical-align:top; width:429.85pt"><p style="margin-left:3.6pt"><strong><em>Nervours system disorders</em></strong></p><p style="margin-left:82.8pt">Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p style="margin-left:82.8pt; margin-right:0cm">Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness, paraesthesia, taste disturbance,</p><p style="margin-left:208.8pt; margin-right:59.4pt">hypoaesthesia, hyperaesthesia, tremor, somnolence</p><p style="margin-left:82.8pt; margin-right:0cm">Very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Convulsions, hypoaesthesia and tetany</p><p style="margin-left:3.6pt; margin-right:81.6pt; text-align:right">(secondary to hypocalcaemia)</p></td></tr><tr><td style="border-color:black; height:65.75pt; vertical-align:top; width:429.85pt"><p style="margin-left:3.6pt"><strong><em>Eye disorders</em></strong></p><p style="margin-left:82.8pt; margin-right:0cm">Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Conjunctivitis</p><p style="margin-left:82.8pt; margin-right:0cm">Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blurred vision, scleritis and orbital</p><p style="margin-left:208.8pt; margin-right:0cm">inflammation</p><p style="margin-left:82.8pt; margin-right:0cm">Very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uveitis, episcleritis</p></td></tr><tr><td style="border-color:black; height:86.9pt; vertical-align:top; width:429.85pt"><p style="margin-left:3.6pt"><strong><em>Cardiac disorders</em></strong></p><p style="margin-left:208.8pt; margin-right:21.6pt; text-indent:-126.0pt">Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypertension, hypotension, atrial fibrillation, hypotension leading to syncope or circulatory collapse</p><p style="margin-left:82.8pt">Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bradycardia</p><p style="margin-left:82.8pt">Very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cardiac arrhythmia (secondary to</p><p style="margin-left:3.6pt; margin-right:153.6pt; text-align:right">hypocalcaemia)</p></td></tr><tr><td style="border-color:black; height:40.3pt; vertical-align:top; width:429.85pt"><p style="margin-left:3.6pt"><strong><em>Respiratory, thoracic and mediastinal disorders</em></strong></p><p style="margin-left:82.8pt">Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dyspnoea, cough, bronchoconstriction</p><p style="margin-left:82.8pt; margin-right:0cm">Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Interstitial lung disease</p></td></tr><tr><td style="border-color:black; height:52.55pt; vertical-align:top; width:429.85pt"><p style="margin-left:3.6pt"><strong><em>Gastrointestinal disorders</em></strong></p><p style="margin-left:82.8pt; margin-right:0cm">Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea, vomiting, anorexia</p><p style="margin-left:82.8pt; margin-right:0cm">Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea, constipation, abdominal pain,</p><p style="margin-left:208.8pt">dyspepsia, stomatitis, dry mouth</p></td></tr><tr><td style="border-color:black; height:39.35pt; vertical-align:top; width:429.85pt"><p style="margin-left:3.6pt"><strong><em>Skin and subcutaneous tissue disorders</em></strong></p><p style="margin-left:82.8pt">Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pruritus, rash (including erythematous and</p><p style="margin-left:208.8pt; margin-right:0cm">macular rash), increased sweating</p></td></tr><tr><td style="border-color:black; height:40.55pt; vertical-align:top; width:429.85pt"><p style="margin-left:3.6pt"><strong><em>Musculoskeletal and connective tissue disorders</em></strong></p><p style="margin-left:82.8pt">Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bone pain, myalgia, arthralgia, generalised pain</p><p style="margin-left:82.8pt; margin-right:0cm">Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle cramps, osteonecrosis of the jaw*</p></td></tr></tbody></table><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="border-color:black; height:39.35pt; vertical-align:top; width:429.85pt"><p style="margin-left:3.6pt; margin-right:0cm"><strong><em>Renal and urinary disorders</em></strong></p><p style="margin-left:79.2pt">Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Renal impairment</p><p style="margin-left:79.2pt"><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
 left:0;text-align:left;margin-left:511.05pt;margin-top:772.75pt;width:18.8pt;
 height:10.9pt;z-index:-251667968;mso-wrap-distance-left:0;
 mso-wrap-distance-right:0;mso-position-horizontal-relative:page;
 mso-position-vertical-relative:page' filled="f" stroked="f">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='margin-top:.55pt;line-height:10.05pt;mso-line-height-rule:
    exactly;vertical-align:baseline'><span style='font-size:9.5pt;mso-bidi-font-size:
    11.0pt;mso-fareast-font-family:"Times New Roman";color:black;letter-spacing:
    1.0pt'>10<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="square" anchorx="page" anchory="page"/>
</v:shape><![endif]--><!--[if !vml]-->Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute renal failure, haematuria, proteinuria</p></td></tr><tr><td style="border-color:black; height:40.55pt; vertical-align:top; width:429.85pt"><p style="margin-left:14.4pt; margin-right:28.8pt"><strong><em>General disorders and administration site conditions</em></strong></p><p style="margin-left:216.0pt; margin-right:57.6pt; text-indent:-126.0pt">Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever, flu-like syndrome (including fatigue, rigors, malaise and flushing)</p><p style="margin-left:216.0pt; margin-right:61.2pt; text-indent:-126.0pt">Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Asthenia, peripheral oedema, injection site reactions (including pain, irritation, swelling, induration), chest pain, weight increase, <u>anaphylactic reaction/shock, urticaria </u></p><p style="margin-left:14.4pt; margin-right:28.8pt">&nbsp;</p></td></tr></tbody></table><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="border-color:black; height:39.35pt; vertical-align:top; width:429.85pt"><p style="margin-left:3.6pt; margin-right:0cm"><strong><em>Investigations</em></strong></p><p style="margin-left:3.6pt">Very common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypophosphataemia</p><p style="margin-left:126.0pt; margin-right:32.4pt; text-indent:-122.4pt">Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood creatinine and blood urea increased, hypocalcaemia</p><p style="margin-left:3.6pt">Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypomagnesaemia, hypokalaemia</p><p style="margin-left:208.8pt; margin-right:0cm">Rare:&nbsp;&nbsp;&nbsp; Hyperkalaemia, hypernatraemia</p></td></tr></tbody></table><p style="margin-left:14.4pt; margin-right:0cm"><u>Description of selected adverse reactions </u></p><p style="margin-left:14.4pt; margin-right:0cm"><em><u>Renal function impairment</u></em></p><p style="margin-left:14.4pt; margin-right:10.8pt">Zoledronic acid, used as indicated in sections 4.1 and 4.2, has been associated with reports of renal dysfunction. . In a pooled analysis of safety data from zoledronic acid registration trials for the prevention of skeletal-related events in patients with advanced malignancies involving bone, the frequency of renal impairment adverse events suspected to be related to zoledronic acid (adverse reactions) was as follows: multiple myeloma (3.2%), prostate cancer (3.1%), breast cancer (4.3%), lung and other solid tumours (3.2%). Factors that may increase the potential for deterioration in renal function include dehydration, pre-existing renal impairment, multiple cycles of zoledronic acid or other bisphosphonates, as well as concomitant use of nephrotoxic medicinal products or using a shorter infusion time than currently recommended. Renal deterioration, progression to renal failure and dialysis have been reported in patients after the initial dose or a single dose of 4 mg zoledronic acid (see section 4.4).</p><p style="margin-left:14.4pt; margin-right:0cm"><em><u>Osteonecrosis of the jaw</u></em></p><p style="margin-left:14.4pt; margin-right:3.6pt">Cases of osteonecrosis (primarily of the jaws) have been reported, predominantly in cancer patients treated with medicinal products that inhibit bone resorption, such as zoledronic acid. Many of these patients had signs of local infection including osteomyelitis, and the majority of the reports refer to cancer patients following tooth extractions or other dental surgeries. Osteonecrosis of the jaws has multiple documented risk factors including a diagnosis of cancer, concomitant therapies (e.g. chemotherapy, radiotherapy, corticosteroids) and co-morbid conditions (e.g. anaemia, coagulopathies, infection, pre-existing oral disease). Although causality has not been determined, it is recommended to avoid dental surgery as recovery may be prolonged (see section 4.4).</p><p style="margin-left:14.4pt; margin-right:0cm"><em><u>Atrial fibrillation </u></em></p><p style="margin-left:3.6pt; margin-right:36.0pt">In one 3-year, randomised, double-blind controlled trial that evaluated the efficacy and safety of zoledronic acid 5 mg once yearly vs. placebo in the treatment of postmenopausal osteoporosis (PMO), the overall incidence of atrial fibrillation was 2.5% (96 out of 3,862) and 1.9% (75 out of 3,852) in patients receiving zoledronic acid 5 mg and placebo, respectively. The rate of atrial fibrillation serious adverse events was 1.3% (51 out of 3,862) and 0.6% (22 out of 3,852) in patients receiving zoledronic acid 5 mg and placebo, respectively. The imbalance observed in this trial has not been observed in other trials with zoledronic acid, including those with zoledronic acid 4 mg every 3-4 weeks in oncology patients. The mechanism behind the increased incidence of atrial fibrillation in this single clinical trial is unknown.</p><p style="margin-left:3.6pt; margin-right:1.8pt"><em><u>Acute phase reaction </u></em></p><p style="margin-left:3.6pt; margin-right:18.0pt">This adverse drug reaction consists of a constellation of symptoms that includes fever, myalgia, headache, extremity pain, nausea, vomiting, diarrhoea and arthralgia with subsequent joint swelling. The onset time is &le; 3 days postzoledronic acid infusion, (used as indicated in section 4.2 and 4.2), and the reaction is also referred to using the terms &ldquo;flu-like&rdquo; or &ldquo;post-dose&rdquo; symptoms.</p><p style="margin-left:3.6pt; margin-right:1.8pt"><em><u>Atypical fractures of the femur</u></em></p><p style="margin-left:3.6pt; margin-right:1.8pt">During post-marketing experience the following reactions have been reported (frequency rare):</p><p style="margin-left:3.6pt; margin-right:1.8pt">Atypical subtrochanteric and diaphyseal femoral fractures (bisphopsphonate class adverse reaction).</p><p style="margin-left:3.6pt; margin-right:1.8pt"><u>Hypocalcaemia-related ADRs </u></p><p style="margin-left:3.6pt; margin-right:1.8pt">Hypocalcaemia is an important identified risk with Zoledronic acid in the approved indications. Based on the review of both clinical trial and post-marketing cases, there is sufficient evidence to support an association between Zoledroinc acid therapy, the reported event of hypocalcaemia, and the secondary development of cardiac arrhythmia. Furthermore, there is evidence of an association between hypocalcaemia and secondary neurological events reported in these cases including; seizures, numbness and tetany (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical experience with acute overdose of zoledronic acid is limited. The administration of doses up to 48 mg of zoledronic acid in error has been reported. Patients who have received doses higher than those recommended (see section 4.2) should be carefully monitored, since renal function impairment (including renal failure) and serum electrolyte (including calcium, phosphorus and magnesium) abnormalities have been observed. In the event of hypocalcaemia, calcium gluconate infusions should be administered as clinically indicated.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs for treatment of bone diseases, bisphosphonate, ATC code:<br />M05BA08<br />Zoledronic acid belongs to the class of bisphosphonates and acts primarily on bone. It is an inhibitor<br />of osteoclastic bone resorption.<br />The selective action of bisphosphonates on bone is based on their high affinity for mineralised bone,<br />but the precise molecular mechanism leading to the inhibition of osteoclastic activity is still unclear.<br />In long-term animal studies, zoledronic acid inhibits bone resorption without adversely affecting the<br />formation, mineralisation or mechanical properties of bone.<br />In addition to being a potent inhibitor of bone resorption, zoledronic acid also possesses several<br />antitumour properties that could contribute to its overall efficacy in the treatment of metastatic bone<br />disease. The following properties have been demonstrated in preclinical studies:<br />- In vivo: Inhibition of osteoclastic bone resorption, which alters the bone marrow<br />microenvironment, making it less conducive to tumour cell growth, anti-angiogenic activity and<br />anti-pain activity.<br />- In vitro: Inhibition of osteoblast proliferation, direct cytostatic and pro-apoptotic activity on<br />tumour cells, synergistic cytostatic effect with other anti-cancer drugs, anti-adhesion/invasion<br />activity.</p><p style="margin-left:3.6pt; margin-right:0cm"><u>Clinical trial results in the prevention of skeletal related events in patients with advanced</u></p><p style="margin-left:3.6pt"><u>malignancies involving bone</u></p><p style="margin-left:3.6pt; margin-right:10.8pt">The first randomised, double-blind, placebo-controlled study compared zoledronic acid 4 mg to placebo for the prevention of skeletal related events (SREs) in prostate cancer patients. Zoledronic acid 4 mg significantly reduced the proportion of patients experiencing at least one skeletal related event (SRE), delayed the median time to first SRE by &gt; 5 months, and reduced the annual incidence of events per patient - skeletal morbidity rate. Multiple event analysis showed a 36% risk reduction in developing SREs in the zoledronic acid 4 mg group compared with placebo. Patients receiving zoledronic acid 4mg reported less increase in pain than those receiving placebo, and the difference reached significance at months 3, 9, 21 and 24. Fewer zoledronic acid 4 mg patients suffered pathological fractures. The treatment effects were less pronounced in patients with blastic lesions. Efficacy results are provided in Table 2.</p><p style="margin-left:3.6pt; margin-right:10.8pt">In a second study including solid tumours other than breast or prostate cancer, Zoledronic acid 4 mg significantly reduced the proportion of patients with an SRE, delayed the median time to first SRE by &gt; 2 months, and reduced the skeletal morbidity rate. Multiple event analysis showed 30.7% risk reduction in developing SREs in the zoledronic acid 4 mg group compared with placebo. Efficacy results are provided in Table 3.</p><p style="margin-left:3.6pt; margin-right:0cm"><strong>Table 2: </strong>Efficacy results (prostate cancer patients receiving hormonal thera</p><p><!--[if !supportMisalignedRows]--></p><p>&nbsp;</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td rowspan="3" style="border-color:black; height:12.25pt; vertical-align:top; width:111.6pt"><p>&nbsp;</p></td><td colspan="2" rowspan="2" style="border-color:black; height:12.25pt; width:117.1pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">Any SRE (+TIH)</p></td><td colspan="2" rowspan="2" style="border-color:black; height:12.25pt; width:117.15pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">Fractures*</p></td><td colspan="2" style="border-color:black; height:12.25pt; width:117.6pt"><p style="text-align:center">Radiation therapy to</p></td><!--[if !supportMisalignedRows]--><td style="height:12.25pt">&nbsp;</td><!--[endif]--></tr><tr><td colspan="2" rowspan="2" style="height:6.25pt; width:117.6pt"><p style="text-align:center">bone</p></td><!--[if !supportMisalignedRows]--><td style="height:6.25pt">&nbsp;</td><!--[endif]--></tr><tr><td colspan="2" style="height:7.2pt; vertical-align:top; width:117.1pt"><p>&nbsp;</p></td><td colspan="2" style="height:7.2pt; vertical-align:top; width:117.15pt"><p>&nbsp;</p></td><td style="height:7.2pt">&nbsp;</td><!--[endif]--></tr><tr><td style="border-color:black; height:26.4pt; vertical-align:top; width:111.6pt"><p>&nbsp;</p></td><td style="height:26.4pt; vertical-align:top; width:63.85pt"><p style="text-align:center">Zoledronic<br />acid 4 mg</p></td><td style="height:26.4pt; width:53.25pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">Placebo</p></td><td style="height:26.4pt; vertical-align:top; width:67.2pt"><p style="text-align:center">Zoledronic<br />acid 4 mg</p></td><td style="height:26.4pt; width:49.95pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">Placebo</p></td><td style="height:26.4pt; vertical-align:top; width:64.05pt"><p style="text-align:center">Zoledronic<br />acid 4 mg</p></td><td style="height:26.4pt; width:53.55pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">Placebo</p></td><!--[if !supportMisalignedRows]--><td style="height:26.4pt">&nbsp;</td><!--[endif]--></tr><tr><td style="border-color:black; height:13.2pt; width:111.6pt"><p style="margin-left:6.0pt">N</p></td><td style="height:13.2pt; width:63.85pt"><p style="margin-right:20.25pt; text-align:right">214</p></td><td style="height:13.2pt; width:53.25pt"><p style="text-align:center">208</p></td><td style="height:13.2pt; width:67.2pt"><p style="margin-right:21.9pt; text-align:right">214</p></td><td style="height:13.2pt; width:49.95pt"><p style="text-align:center">208</p></td><td style="height:13.2pt; width:64.05pt"><p style="margin-right:20.45pt; text-align:right">214</p></td><td style="height:13.2pt; width:53.55pt"><p style="text-align:center">208</p></td><!--[if !supportMisalignedRows]--><td style="height:13.2pt">&nbsp;</td><!--[endif]--></tr><tr><td style="border-color:black; height:25.65pt; vertical-align:top; width:111.6pt"><p style="margin-left:5.4pt">Proportion of patients with SREs (%)</p></td><td style="height:25.65pt; width:63.85pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">38</p></td><td style="height:25.65pt; width:53.25pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">49</p></td><td style="height:25.65pt; width:67.2pt"><p style="margin-left:0cm; margin-right:21.9pt; text-align:right">17</p></td><td style="height:25.65pt; width:49.95pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">25</p></td><td style="height:25.65pt; width:64.05pt"><p style="margin-left:0cm; margin-right:20.45pt; text-align:right">26</p></td><td style="height:25.65pt; width:53.55pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">33</p></td><!--[if !supportMisalignedRows]--><td style="height:25.65pt">&nbsp;</td><!--[endif]--></tr><tr><td style="border-color:black; height:13.2pt; width:111.6pt"><p style="margin-left:6.0pt">p-value</p></td><td colspan="2" style="height:13.2pt; width:117.1pt"><p style="margin-right:42.75pt; text-align:right">0.028</p></td><td colspan="2" style="height:13.2pt; width:117.15pt"><p style="margin-right:44.4pt; text-align:right">0.052</p></td><td colspan="2" style="height:13.2pt; width:117.6pt"><p style="margin-right:42.95pt; text-align:right">0.119</p></td><!--[if !supportMisalignedRows]--><td style="height:13.2pt">&nbsp;</td><!--[endif]--></tr><tr><td style="border-color:black; height:25.7pt; vertical-align:top; width:111.6pt"><p style="margin-left:5.4pt">Median time to SRE (days)</p></td><td style="height:25.7pt; width:63.85pt"><p style="margin-left:0cm; margin-right:20.25pt; text-align:right">488</p></td><td style="height:25.7pt; width:53.25pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">321</p></td><td style="height:25.7pt; width:67.2pt"><p style="margin-left:0cm; margin-right:21.9pt; text-align:right">NR</p></td><td style="height:25.7pt; width:49.95pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">NR</p></td><td style="height:25.7pt; width:64.05pt"><p style="margin-left:0cm; margin-right:20.45pt; text-align:right">NR</p></td><td style="height:25.7pt; width:53.55pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">640</p></td><!--[if !supportMisalignedRows]--><td style="height:25.7pt">&nbsp;</td><!--[endif]--></tr><tr><td style="border-color:black; height:13.2pt; width:111.6pt"><p style="margin-left:6.0pt">p-value</p></td><td colspan="2" style="height:13.2pt; width:117.1pt"><p style="margin-right:42.75pt; text-align:right">0.009</p></td><td colspan="2" style="height:13.2pt; width:117.15pt"><p style="margin-right:39.9pt; text-align:right">0.020</p></td><td colspan="2" style="height:13.2pt; width:117.6pt"><p style="margin-right:42.95pt; text-align:right">0.055</p></td><!--[if !supportMisalignedRows]--><td style="height:13.2pt">&nbsp;</td><!--[endif]--></tr><tr><td style="border-color:black; height:25.9pt; vertical-align:top; width:111.6pt"><p style="margin-left:5.4pt">Skeletal morbidity<br />rate</p></td><td style="height:25.9pt; width:63.85pt"><p style="margin-left:0cm; margin-right:20.25pt; text-align:right">0.77</p></td><td style="height:25.9pt; width:53.25pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">1.47</p></td><td style="height:25.9pt; width:67.2pt"><p style="margin-left:0cm; margin-right:21.9pt; text-align:right">0.20</p></td><td style="height:25.9pt; width:49.95pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">0.45</p></td><td style="height:25.9pt; width:64.05pt"><p style="margin-left:0cm; margin-right:20.45pt; text-align:right">0.42</p></td><td style="height:25.9pt; width:53.55pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">0.89</p></td><!--[if !supportMisalignedRows]--><td style="height:25.9pt">&nbsp;</td><!--[endif]--></tr><tr><td style="border-color:black; height:12.95pt; width:111.6pt"><p style="margin-left:6.0pt">p-value</p></td><td colspan="2" style="height:12.95pt; width:117.1pt"><p style="margin-right:42.75pt; text-align:right">0.005</p></td><td colspan="2" style="height:12.95pt; width:117.15pt"><p style="margin-right:44.4pt; text-align:right">0.023</p></td><td colspan="2" style="height:12.95pt; width:117.6pt"><p style="margin-right:42.95pt; text-align:right">0.060</p></td><!--[if !supportMisalignedRows]--><td style="height:12.95pt">&nbsp;</td><!--[endif]--></tr><tr><td style="border-color:black; height:38.4pt; vertical-align:top; width:111.6pt"><p style="margin-left:5.4pt; margin-right:7.2pt">Risk reduction of suffering from multiple events** (%)</p></td><td style="height:38.4pt; width:63.85pt"><p style="margin-left:0cm; margin-right:20.25pt; text-align:right">36</p></td><td style="height:38.4pt; width:53.25pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">-</p></td><td style="height:38.4pt; width:67.2pt"><p style="margin-left:0cm; margin-right:21.9pt; text-align:right">NA</p></td><td style="height:38.4pt; width:49.95pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">NA</p></td><td style="height:38.4pt; width:64.05pt"><p style="margin-left:0cm; margin-right:20.45pt; text-align:right">NA</p></td><td style="height:38.4pt; width:53.55pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">NA</p></td><!--[if !supportMisalignedRows]--><td style="height:38.4pt">&nbsp;</td><!--[endif]--></tr><tr><td style="border-color:black; height:13.9pt; width:111.6pt"><p style="margin-left:6.0pt">p-value</p></td><td colspan="2" style="height:13.9pt; width:117.1pt"><p style="margin-right:42.75pt; text-align:right">0.002</p></td><td colspan="2" style="height:13.9pt; width:117.15pt"><p style="margin-right:44.4pt; text-align:right">NA</p></td><td colspan="2" style="height:13.9pt; width:117.6pt"><p style="margin-right:42.95pt; text-align:right">NA</p></td><!--[if !supportMisalignedRows]--><td style="height:13.9pt">&nbsp;</td><!--[endif]--></tr></tbody></table><p style="margin-left:3.6pt">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Includes vertebral and non-vertebral fractures</p><p style="margin-left:3.6pt">**&nbsp;&nbsp;&nbsp; Accounts for all skeletal events, the total number as well as time to each event during the trial</p><p style="margin-left:3.6pt; margin-right:0cm">NR Not Reached</p><p style="margin-left:3.6pt">NA Not Applicable</p><p style="margin-left:3.6pt; margin-right:0cm"><strong>Table 3: </strong>Efficacy results (solid tumours other than breast or prostate cancer)</p><p>&nbsp;</p><p><!--[if !supportMisalignedRows]--></p><p>&nbsp;</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td rowspan="3" style="border-color:black; height:12.25pt; vertical-align:top; width:111.6pt"><p>&nbsp;</p></td><td colspan="2" rowspan="2" style="border-color:black; height:12.25pt; width:117.1pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">Any SRE (+TIH)</p></td><td colspan="2" rowspan="2" style="border-color:black; height:12.25pt; width:117.15pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">Fractures*</p></td><td colspan="2" style="border-color:black; height:12.25pt; width:117.6pt"><p style="text-align:center">Radiation therapy to</p></td><!--[if !supportMisalignedRows]--><td style="height:12.25pt">&nbsp;</td><!--[endif]--></tr><tr><td colspan="2" rowspan="2" style="height:6.25pt; width:117.6pt"><p style="text-align:center">bone</p></td><!--[if !supportMisalignedRows]--><td style="height:6.25pt">&nbsp;</td><!--[endif]--></tr><tr><td colspan="2" style="height:6.95pt; vertical-align:top; width:117.1pt"><p>&nbsp;</p></td><td colspan="2" style="height:6.95pt; vertical-align:top; width:117.15pt"><p>&nbsp;</p></td><td style="height:6.95pt">&nbsp;</td><!--[endif]--></tr><tr><td style="border-color:black; height:26.65pt; vertical-align:top; width:111.6pt"><p>&nbsp;</p></td><td style="height:26.65pt; vertical-align:top; width:63.85pt"><p style="text-align:center">Zoledronic<br />acid 4 mg</p></td><td style="height:26.65pt; width:53.25pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">Placebo</p></td><td style="height:26.65pt; vertical-align:top; width:67.2pt"><p style="text-align:center">Zoledronic<br />acid 4 mg</p></td><td style="height:26.65pt; width:49.95pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">Placebo</p></td><td style="height:26.65pt; vertical-align:top; width:64.05pt"><p style="text-align:center">Zoledronic<br />acid 4 mg</p></td><td style="height:26.65pt; width:53.55pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">Placebo</p></td><!--[if !supportMisalignedRows]--><td style="height:26.65pt">&nbsp;</td><!--[endif]--></tr><tr><td style="border-color:black; height:13.2pt; width:111.6pt"><p style="margin-left:6.0pt">N</p></td><td style="height:13.2pt; width:63.85pt"><p style="text-align:center">257</p></td><td style="height:13.2pt; width:53.25pt"><p style="text-align:center">250</p></td><td style="height:13.2pt; width:67.2pt"><p style="text-align:center">257</p></td><td style="height:13.2pt; width:49.95pt"><p style="text-align:center">250</p></td><td style="height:13.2pt; width:64.05pt"><p style="text-align:center">257</p></td><td style="height:13.2pt; width:53.55pt"><p style="text-align:center">250</p></td><!--[if !supportMisalignedRows]--><td style="height:13.2pt">&nbsp;</td><!--[endif]--></tr><tr><td style="border-color:black; height:13.9pt; width:111.6pt"><p style="margin-left:6.0pt; margin-right:0cm">Proportion of patients</p></td><td style="height:13.9pt; width:63.85pt"><p style="text-align:center">39</p></td><td style="height:13.9pt; width:53.25pt"><p style="text-align:center">48</p></td><td style="height:13.9pt; width:67.2pt"><p style="text-align:center">16</p></td><td style="height:13.9pt; width:49.95pt"><p style="text-align:center">22</p></td><td style="height:13.9pt; width:64.05pt"><p style="text-align:center">29</p></td><td style="height:13.9pt; width:53.55pt"><p style="text-align:center">34</p></td><!--[if !supportMisalignedRows]--><td style="height:13.9pt">&nbsp;</td><!--[endif]--></tr></tbody></table><table cellspacing="0" cellpadding="0" border="1" style="width:621px"><tbody><tr><td style="border-color:black; height:13.7pt; width:111.6pt"><p style="margin-left:6.0pt">with SREs (%)</p></td><td style="height:13.7pt; vertical-align:top; width:44.4pt"><p>&nbsp;</p></td><td style="border-color:black; height:13.7pt; vertical-align:top; width:19.45pt"><p>&nbsp;</p></td><td style="border-color:black; height:13.7pt; vertical-align:top; width:53.25pt"><p>&nbsp;</p></td><td style="height:13.7pt; vertical-align:top; width:45.4pt"><p>&nbsp;</p></td><td style="border-color:black; height:13.7pt; vertical-align:top; width:21.8pt"><p>&nbsp;</p></td><td style="border-color:black; height:13.7pt; vertical-align:top; width:49.95pt"><p>&nbsp;</p></td><td style="height:13.7pt; vertical-align:top; width:44.4pt"><p>&nbsp;</p></td><td style="border-color:black; height:13.7pt; vertical-align:top; width:19.65pt"><p>&nbsp;</p></td><td style="border-color:black; height:13.7pt; vertical-align:top; width:113px"><p>&nbsp;</p></td></tr><tr><td style="border-color:black; height:13.2pt; width:111.6pt"><p style="margin-left:6.0pt">p-value</p></td><td style="height:13.2pt; vertical-align:top; width:44.4pt"><p>&nbsp;</p></td><td colspan="2" style="height:13.2pt; width:72.7pt"><p>0.039</p></td><td style="height:13.2pt; vertical-align:top; width:45.4pt"><p>&nbsp;</p></td><td colspan="2" style="height:13.2pt; width:71.75pt"><p>0.064</p></td><td style="height:13.2pt; vertical-align:top; width:44.4pt"><p>&nbsp;</p></td><td colspan="2" style="height:13.2pt; width:138px"><p>0.173</p></td></tr><tr><td style="border-color:black; height:25.65pt; vertical-align:top; width:111.6pt"><p style="margin-left:5.4pt">Median time to SRE (days)</p></td><td style="height:25.65pt; width:44.4pt"><p style="margin-left:0cm; margin-right:3.15pt; text-align:right">236</p></td><td style="height:25.65pt; vertical-align:top; width:19.45pt"><p>&nbsp;</p></td><td style="height:25.65pt; width:53.25pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">155</p></td><td style="height:25.65pt; width:45.4pt"><p style="margin-left:0cm; margin-right:2.2pt; text-align:right">NR</p></td><td style="height:25.65pt; vertical-align:top; width:21.8pt"><p>&nbsp;</p></td><td style="height:25.65pt; width:49.95pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">NR</p></td><td style="height:25.65pt; width:44.4pt"><p style="margin-left:0cm; margin-right:3.15pt; text-align:right">424</p></td><td style="height:25.65pt; vertical-align:top; width:19.65pt"><p>&nbsp;</p></td><td style="height:25.65pt; width:113px"><p style="margin-left:0cm; margin-right:0cm; text-align:center">307</p></td></tr><tr><td style="border-color:black; height:13.2pt; width:111.6pt"><p style="margin-left:6.0pt">p-value</p></td><td style="height:13.2pt; vertical-align:top; width:44.4pt"><p>&nbsp;</p></td><td colspan="2" style="height:13.2pt; width:72.7pt"><p>0.009</p></td><td style="height:13.2pt; vertical-align:top; width:45.4pt"><p>&nbsp;</p></td><td colspan="2" style="height:13.2pt; width:71.75pt"><p>0.020</p></td><td style="height:13.2pt; vertical-align:top; width:44.4pt"><p>&nbsp;</p></td><td colspan="2" style="height:13.2pt; width:138px"><p>0.079</p></td></tr><tr><td style="border-color:black; height:25.7pt; vertical-align:top; width:111.6pt"><p style="margin-left:5.4pt">Skeletal morbidity<br />rate</p></td><td style="height:25.7pt; width:44.4pt"><p style="margin-left:0cm; margin-right:3.15pt; text-align:right">1.74</p></td><td style="height:25.7pt; vertical-align:top; width:19.45pt"><p>&nbsp;</p></td><td style="height:25.7pt; width:53.25pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">2.71</p></td><td style="height:25.7pt; width:45.4pt"><p style="margin-left:0cm; margin-right:2.2pt; text-align:right">0.39</p></td><td style="height:25.7pt; vertical-align:top; width:21.8pt"><p>&nbsp;</p></td><td style="height:25.7pt; width:49.95pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">0.63</p></td><td style="height:25.7pt; width:44.4pt"><p style="margin-left:0cm; margin-right:3.15pt; text-align:right">1.24</p></td><td style="height:25.7pt; vertical-align:top; width:19.65pt"><p>&nbsp;</p></td><td style="height:25.7pt; width:113px"><p style="margin-left:0cm; margin-right:0cm; text-align:center">1.89</p></td></tr><tr><td style="border-color:black; height:13.2pt; width:111.6pt"><p style="margin-left:6.0pt">p-value</p></td><td style="height:13.2pt; vertical-align:top; width:44.4pt"><p>&nbsp;</p></td><td colspan="2" style="height:13.2pt; width:72.7pt"><p>0.012</p></td><td style="height:13.2pt; vertical-align:top; width:45.4pt"><p>&nbsp;</p></td><td colspan="2" style="height:13.2pt; width:71.75pt"><p>0.066</p></td><td style="height:13.2pt; vertical-align:top; width:44.4pt"><p>&nbsp;</p></td><td colspan="2" style="height:13.2pt; width:138px"><p>0.099</p></td></tr><tr><td style="border-color:black; height:38.4pt; vertical-align:top; width:111.6pt"><p style="margin-left:5.4pt; margin-right:7.2pt">Risk reduction of suffering from multiple events** (%)</p></td><td style="height:38.4pt; width:44.4pt"><p style="margin-left:0cm; margin-right:3.15pt; text-align:right">30.7</p></td><td style="height:38.4pt; vertical-align:top; width:19.45pt"><p>&nbsp;</p></td><td style="height:38.4pt; width:53.25pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">-</p></td><td style="height:38.4pt; width:45.4pt"><p style="margin-left:0cm; margin-right:2.2pt; text-align:right">NA</p></td><td style="height:38.4pt; vertical-align:top; width:21.8pt"><p>&nbsp;</p></td><td style="height:38.4pt; width:49.95pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">NA</p></td><td style="height:38.4pt; width:44.4pt"><p style="margin-left:0cm; margin-right:3.15pt; text-align:right">NA</p></td><td style="height:38.4pt; vertical-align:top; width:19.65pt"><p>&nbsp;</p></td><td style="height:38.4pt; width:113px"><p style="margin-left:0cm; margin-right:0cm; text-align:center">NA</p></td></tr><tr><td style="border-color:black; height:13.65pt; width:111.6pt"><p style="margin-left:6.0pt">p-value</p></td><td style="height:13.65pt; vertical-align:top; width:44.4pt"><p>&nbsp;</p></td><td colspan="2" style="height:13.65pt; width:72.7pt"><p>0.003</p></td><td style="height:13.65pt; vertical-align:top; width:45.4pt"><p>&nbsp;</p></td><td colspan="2" style="height:13.65pt; width:71.75pt"><p style="margin-right:43.95pt; text-align:right">NA</p></td><td style="height:13.65pt; vertical-align:top; width:44.4pt"><p>&nbsp;</p></td><td colspan="2" style="height:13.65pt; width:138px"><p style="margin-right:44.65pt; text-align:right">NA</p></td></tr></tbody></table><p style="margin-left:3.6pt">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Includes vertebral and non-vertebral fractures</p><p style="margin-left:3.6pt">**&nbsp;&nbsp;&nbsp; Accounts for all skeletal events, the total number as well as time to each event during the trial</p><p style="margin-left:3.6pt">NR Not Reached</p><p style="margin-left:3.6pt">NA Not Applicable</p><p style="margin-left:3.6pt; margin-right:7.2pt">In a third phase III randomised, double-blind trial, zoledronic acid 4 mg or 90 mg pamidronate every 3 to 4 weeks were compared in patients with multiple myeloma or breast cancer with at least one bone lesion. The results demonstrated that Zoledronic acid 4 mg showed comparable efficacy to 90 mg pamidronate in the prevention of SREs. The multiple event analysis revealed a significant risk reduction of 16% in patients treated with Zoledronic acid 4 mg in comparison with patients receiving pamidronate. Efficacy results are provided in Table 4.</p><p style="margin-left:3.6pt; margin-right:0cm"><strong>Table 4: </strong>Efficacy results (breast cancer and multiple myeloma patients)</p><p><!--[if !supportMisalignedRows]--></p><p>&nbsp;</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td rowspan="3" style="border-color:black; height:12.25pt; vertical-align:top; width:106.1pt"><p>&nbsp;</p></td><td colspan="2" rowspan="2" style="border-color:black; height:12.25pt; width:117.1pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">Any SRE (+TIH)</p></td><td colspan="2" rowspan="2" style="border-color:black; height:12.25pt; width:117.1pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">Fractures*</p></td><td colspan="2" style="border-color:black; height:12.25pt; width:179px"><p style="text-align:center">Radiation therapy to</p></td><!--[if !supportMisalignedRows]--><!--[endif]--></tr><tr><td colspan="2" rowspan="2" style="height:6.25pt; width:179px"><p style="text-align:center">bone</p></td><!--[if !supportMisalignedRows]--><!--[endif]--></tr><tr><td colspan="2" style="height:6.95pt; vertical-align:top; width:117.1pt"><p>&nbsp;</p></td><td colspan="2" style="height:6.95pt; vertical-align:top; width:117.1pt"><p>&nbsp;</p></td><!--[endif]--></tr><tr><td style="border-color:black; height:26.65pt; vertical-align:top; width:106.1pt"><p>&nbsp;</p></td><td style="height:26.65pt; vertical-align:top; width:63.8pt"><p style="text-align:center">Zoledronic<br />acid 4 mg</p></td><td style="height:26.65pt; vertical-align:top; width:53.3pt"><p style="text-align:center">Pam 90<br />mg</p></td><td style="height:26.65pt; vertical-align:top; width:67.2pt"><p style="text-align:center">Zoledronic<br />acid 4 mg</p></td><td style="height:26.65pt; vertical-align:top; width:49.9pt"><p style="text-align:center">Pam 90<br />mg</p></td><td style="height:26.65pt; vertical-align:top; width:64.1pt"><p style="text-align:center">Zoledronic<br />acid 4 mg</p></td><td style="height:26.65pt; vertical-align:top; width:96px"><p style="text-align:center">Pam 90<br />mg</p></td><!--[if !supportMisalignedRows]--><!--[endif]--></tr><tr><td style="border-color:black; height:13.2pt; width:106.1pt"><p style="margin-left:5.55pt">N</p></td><td style="height:13.2pt; width:63.8pt"><p style="margin-right:20.2pt; text-align:right">561</p></td><td style="height:13.2pt; width:53.3pt"><p style="text-align:center">555</p></td><td style="height:13.2pt; width:67.2pt"><p style="margin-right:21.9pt; text-align:right">561</p></td><td style="height:13.2pt; width:49.9pt"><p style="text-align:center">555</p></td><td style="height:13.2pt; width:64.1pt"><p style="margin-right:20.45pt; text-align:right">561</p></td><td style="height:13.2pt; width:96px"><p style="text-align:center">555</p></td><!--[if !supportMisalignedRows]--><!--[endif]--></tr><tr><td style="border-color:black; height:38.4pt; vertical-align:top; width:106.1pt"><p style="margin-left:5.4pt; margin-right:21.6pt">Proportion of patients with SREs (%)</p></td><td style="height:38.4pt; width:63.8pt"><p style="margin-left:0cm; margin-right:24.7pt; text-align:right">48</p></td><td style="height:38.4pt; width:53.3pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">52</p></td><td style="height:38.4pt; width:67.2pt"><p style="margin-left:0cm; margin-right:21.9pt; text-align:right">37</p></td><td style="height:38.4pt; width:49.9pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">39</p></td><td style="height:38.4pt; width:64.1pt"><p style="margin-left:0cm; margin-right:20.45pt; text-align:right">19</p></td><td style="height:38.4pt; width:96px"><p style="margin-left:0cm; margin-right:0cm; text-align:center">24</p></td><!--[if !supportMisalignedRows]--><!--[endif]--></tr><tr><td style="border-color:black; height:12.95pt; width:106.1pt"><p style="margin-left:5.55pt">p-value</p></td><td colspan="2" style="height:12.95pt; width:117.1pt"><p style="margin-right:42.7pt; text-align:right">0.198</p></td><td colspan="2" style="height:12.95pt; width:117.1pt"><p style="margin-left:44.4pt">0.653</p></td><td colspan="2" style="height:12.95pt; width:179px"><p style="margin-right:42.95pt; text-align:right">0.037</p></td><!--[if !supportMisalignedRows]--><!--[endif]--></tr><tr><td style="border-color:black; height:25.9pt; vertical-align:top; width:106.1pt"><p style="margin-left:5.4pt">Median time to SRE (days)</p></td><td style="height:25.9pt; width:63.8pt"><p style="margin-left:0cm; margin-right:20.2pt; text-align:right">376</p></td><td style="height:25.9pt; width:53.3pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">356</p></td><td style="height:25.9pt; width:67.2pt"><p style="margin-left:0cm; margin-right:21.9pt; text-align:right">NR</p></td><td style="height:25.9pt; width:49.9pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">714</p></td><td style="height:25.9pt; width:64.1pt"><p style="margin-left:0cm; margin-right:20.45pt; text-align:right">NR</p></td><td style="height:25.9pt; width:96px"><p style="margin-left:0cm; margin-right:0cm; text-align:center">NR</p></td><!--[if !supportMisalignedRows]--><!--[endif]--></tr><tr><td style="border-color:black; height:13.2pt; width:106.1pt"><p style="margin-left:5.55pt">p-value</p></td><td colspan="2" style="height:13.2pt; width:117.1pt"><p style="margin-right:42.7pt; text-align:right">0.151</p></td><td colspan="2" style="height:13.2pt; width:117.1pt"><p style="margin-left:44.4pt">0.672</p></td><td colspan="2" style="height:13.2pt; width:179px"><p style="margin-right:42.95pt; text-align:right">0.026</p></td><!--[if !supportMisalignedRows]--><!--[endif]--></tr><tr><td style="border-color:black; height:25.7pt; vertical-align:top; width:106.1pt"><p style="margin-left:5.4pt; margin-right:23.4pt">Skeletal morbidity rate</p></td><td style="height:25.7pt; width:63.8pt"><p style="margin-left:0cm; margin-right:20.2pt; text-align:right">1.04</p></td><td style="height:25.7pt; width:53.3pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">1.39</p></td><td style="height:25.7pt; width:67.2pt"><p style="margin-left:0cm; margin-right:21.9pt; text-align:right">0.53</p></td><td style="height:25.7pt; width:49.9pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">0.60</p></td><td style="height:25.7pt; width:64.1pt"><p style="margin-left:0cm; margin-right:20.45pt; text-align:right">0.47</p></td><td style="height:25.7pt; width:96px"><p style="margin-left:0cm; margin-right:0cm; text-align:center">0.71</p></td><!--[if !supportMisalignedRows]--><!--[endif]--></tr><tr><td style="border-color:black; height:13.2pt; width:106.1pt"><p style="margin-left:5.55pt">p-value</p></td><td colspan="2" style="height:13.2pt; width:117.1pt"><p style="margin-right:42.7pt; text-align:right">0.084</p></td><td colspan="2" style="height:13.2pt; width:117.1pt"><p style="margin-left:44.4pt">0.614</p></td><td colspan="2" style="height:13.2pt; width:179px"><p style="margin-right:42.95pt; text-align:right">0.015</p></td><!--[if !supportMisalignedRows]--><!--[endif]--></tr><tr><td style="border-color:black; height:50.85pt; vertical-align:top; width:106.1pt"><p style="margin-left:5.4pt">Risk reduction of<br />suffering from<br />multiple events**<br />(%)</p></td><td style="height:50.85pt; width:63.8pt"><p style="margin-left:0cm; margin-right:20.2pt; text-align:right">16</p></td><td style="height:50.85pt; width:53.3pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">-</p></td><td style="height:50.85pt; width:67.2pt"><p style="margin-left:0cm; margin-right:21.9pt; text-align:right">NA</p></td><td style="height:50.85pt; width:49.9pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">NA</p></td><td style="height:50.85pt; width:64.1pt"><p style="margin-left:0cm; margin-right:20.45pt; text-align:right">NA</p></td><td style="height:50.85pt; width:96px"><p style="margin-left:0cm; margin-right:0cm; text-align:center">NA</p></td><!--[if !supportMisalignedRows]--><!--[endif]--></tr><tr><td style="border-color:black; height:13.7pt; width:106.1pt"><p style="margin-left:5.55pt">p-value</p></td><td colspan="2" style="height:13.7pt; width:117.1pt"><p style="margin-right:42.7pt; text-align:right">0.030</p></td><td colspan="2" style="height:13.7pt; width:117.1pt"><p style="margin-right:44.4pt; text-align:right">NA</p></td><td colspan="2" style="height:13.7pt; width:179px"><p style="margin-right:42.95pt; text-align:right">NA</p></td><!--[if !supportMisalignedRows]--><!--[endif]--></tr></tbody></table><p style="margin-left:3.6pt">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Includes vertebral and non-vertebral fractures</p><p style="margin-left:3.6pt">**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accounts for all skeletal events, the total number as well as time to each event during the trial</p><p style="margin-left:3.6pt">NR Not Reached</p><p style="margin-left:3.6pt; margin-right:0cm">NA Not Applicable</p><p>&nbsp;</p><p>15</p><p>&nbsp;</p><p style="margin-left:21.6pt; margin-right:14.4pt; text-align:justify">Zoledronic acid 4mg was also studied in a double-blind, randomised, placebo-controlled trial in 228 patients with documented bone metastases from breast cancer to evaluate the effect of 4 mg zoledronic acid on the skeletal related event (SRE) rate ratio, calculated as the total number of SRE events (excluding hypercalcaemia and adjusted for prior fracture), divided by the total risk period. Patients received either 4 mg zoledronic acid or placebo every four weeks for one year. Patients were evenly distributed between zoledronic acid-treated and placebo groups.</p><p style="margin-left:21.6pt; margin-right:0cm">The SRE rate (events/person year) was 0.628 for zoledronic acid and 1.096 for placebo. The proportion of patients with at least one SRE (excluding hypercalcaemia) was 29.8% in the zoledronic acid-treated group versus 49.6% in the placebo group (p=0.003). Median time to onset of the first SRE was not reached in the zoledronic acid-treated arm at the end of the study and was significantly prolonged compared to placebo (p=0.007). Zoledronic acid 4 mg reduced the risk of SREs by 41% in a multiple event analysis (risk ratio=0.59, p=0.019) compared with placebo.</p><p style="margin-left:21.6pt; margin-right:14.4pt">In the zoledronic acid-treated group, statistically significant improvement in pain scores (using the Brief Pain Inventory, BPI) was seen at 4 weeks and at every subsequent time point during the study, when compared to placebo (Figure 1). The pain score for zoledronic acid was consistently below baseline and pain reduction was accompanied by a trend in reduced analgesics score.</p><p style="margin-left:0cm; margin-right:0cm; text-align:center"><strong>Figure 1. Mean changes from baseline in BPI scores. Statistically significant differences are<br />marked (*p&lt;0.05) for between treatment comparisons (4 mg zoledronic acid vs. Placebo)</strong></p><p style="margin-left:0cm; margin-right:0cm; text-align:center">&nbsp;</p><p style="margin-left:0cm; margin-right:0cm; text-align:center"><img src="data:image/jpeg;base64,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" alt="" style="width:981px;height:711px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" width="981" vspace="0" hspace="0" height="711" border="0" /></p><p style="margin-left:0cm; margin-right:0cm; text-align:center">&nbsp;</p><p style="margin-left:0cm; margin-right:0cm; text-align:center">&nbsp;</p><p style="margin-left:21.6pt; margin-right:0cm"><u>Clinical trial results in the treatment of TIH</u></p><p style="margin-left:21.6pt">Clinical studies in tumour-induced hypercalcaemia (TIH) demonstrated that the effect of zoledronic</p><p>acid is characterised by decreases in serum calcium and urinary calcium excretion. In Phase I dosefinding studies in patients with mild to moderate tumour-induced hypercalcaemia (TIH), effective doses tested were in the range of approximately 1.2&ndash;2.5 mg.</p><p style="margin-left:3.6pt; margin-right:14.4pt">To assess the effects of 4 mg zoledronic acid versus pamidronate 90 mg, the results of two pivotal multicentre studies in patients with TIH were combined in a pre-planned analysis. There was faster normalisation of corrected serum calcium at day 4 for 8 mg zoledronic acid and at day 7 for 4 mg and 8 mg zoledronic acid 4 mg and 8 mg. The following response rates were observed:</p><p style="margin-left:3.6pt; margin-right:0cm"><strong>Table 5: </strong>Proportion of complete responders by day in the combined TIH studies</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="border-color:black; height:13.7pt; vertical-align:top; width:142.1pt"><p>&nbsp;</p></td><td style="height:13.7pt; width:38.4pt"><p style="text-align:center">Day 4</p></td><td style="border-color:black; height:13.7pt; vertical-align:top; width:66.7pt"><p>&nbsp;</p></td><td style="height:13.7pt; width:38.15pt"><p style="margin-right:6.4pt; text-align:right">Day 7</p></td><td style="border-color:black; height:13.7pt; vertical-align:top; width:66.75pt"><p>&nbsp;</p></td><td style="height:13.7pt; width:38.6pt"><p style="text-align:center">Day 10</p></td><td style="border-color:black; height:13.7pt; vertical-align:top; width:67.2pt"><p>&nbsp;</p></td></tr><tr><td style="border-color:black; height:13.2pt; width:142.1pt"><p style="margin-left:6.25pt">Zoledronic acid 4 mg (N=86)</p></td><td style="height:13.2pt; width:38.4pt"><p>45.3%</p></td><td style="height:13.2pt; width:66.7pt"><p style="margin-left:1.65pt">(p=0.104)</p></td><td style="height:13.2pt; width:38.15pt"><p>82.6%</p></td><td style="height:13.2pt; width:66.75pt"><p style="margin-right:17.55pt; text-align:right">(p=0.005)*</p></td><td style="height:13.2pt; width:38.6pt"><p>88.4%</p></td><td style="height:13.2pt; width:67.2pt"><p style="margin-right:18.25pt; text-align:right">(p=0.002)*</p></td></tr><tr><td style="border-color:black; height:12.95pt; width:142.1pt"><p style="margin-left:6.25pt">Zoledronic acid 8 mg (N=90)</p></td><td style="height:12.95pt; width:38.4pt"><p>55.6%</p></td><td style="height:12.95pt; width:66.7pt"><p style="margin-left:1.65pt">(p=0.021)*</p></td><td style="height:12.95pt; width:38.15pt"><p>83.3%</p></td><td style="height:12.95pt; width:66.75pt"><p style="margin-right:17.55pt; text-align:right">(p=0.010)*</p></td><td style="height:12.95pt; width:38.6pt"><p>86.7%</p></td><td style="height:12.95pt; width:67.2pt"><p style="margin-right:18.25pt; text-align:right">(p=0.015)*</p></td></tr><tr><td style="border-color:black; height:13.2pt; width:142.1pt"><p style="margin-left:6.25pt">Pamidronate 90 mg (N=99)</p></td><td style="height:13.2pt; width:38.4pt"><p>33.3%</p></td><td style="height:13.2pt; vertical-align:top; width:66.7pt"><p>&nbsp;</p></td><td style="height:13.2pt; width:38.15pt"><p>63.6%</p></td><td style="height:13.2pt; vertical-align:top; width:66.75pt"><p>&nbsp;</p></td><td style="height:13.2pt; width:38.6pt"><p>69.7%</p></td><td style="height:13.2pt; vertical-align:top; width:67.2pt"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="height:13.95pt; width:180.5pt"><p style="margin-left:6.25pt; margin-right:0cm">* p-values compared to pamidronate.</p></td><td colspan="2" style="height:13.95pt; vertical-align:top; width:104.85pt"><p>&nbsp;</p></td><td colspan="2" style="height:13.95pt; vertical-align:top; width:105.35pt"><p>&nbsp;</p></td><td style="height:13.95pt; vertical-align:top; width:67.2pt"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p style="margin-left:3.6pt; margin-right:14.4pt">Median time to normocalcaemia was 4 days. Median time to relapse (re-increase of albumin-corrected serum calcium &ge; 2.9 mmol/l) was 30 to 40 days for patients treated with zoledronic acid versus 17 days for those treated with pamidronate 90 mg (p-values: 0.001 for 4 mg and 0.007 for 8 mg zoledronic acid). There were no statistically significant differences between the two zoledronic acid doses.</p><p style="margin-left:3.6pt; margin-right:14.4pt">In clinical trials 69 patients who relapsed or were refractory to initial treatment (zoledronic acid 4 mg, 8 mg or pamidronate 90 mg) were retreated with 8 mg zoledronic acid. The response rate in these patients was about 52%. Since those patients were retreated with the 8 mg dose only, there are no data available allowing comparison with the 4 mg zoledronic acid dose.</p><p style="margin-left:3.6pt; margin-right:14.4pt">In clinical trials performed in patients with tumour-induced hypercalcaemia (TIH), the overall safety profile amongst all three treatment groups (zoledronic acid 4 and 8 mg and pamidronate 90 mg) was similar in types and severity.</p><p style="margin-left:3.6pt; margin-right:0cm"><u>Paediatric population</u></p><p style="margin-left:3.6pt; margin-right:28.8pt"><em><u>Clinical trial results in the treatment of severe osteogenesis imperfecta in paediatric patients aged </u></em><em><u>] </u></em><em><u>to </u></em><em><u>]</u></em><em><u>7 years</u></em></p><p style="margin-left:3.6pt; margin-right:14.4pt">The effects of intravenous zoledronic acid in the treatment of paediatric patients (age 1 to 17 years) with severe osteogenesis imperfecta (types I, III and IV) were compared to intravenous pamidronate in one international, multicentre, randomised, open-label study with 74 and 76 patients in each treatment group, respectively. The study treatment period was 12 months preceded by a 4- to 9-week screening period during which vitamin D and elemental calcium supplements were taken for at least 2 weeks. In the clinical programme patients aged 1 to &lt; 3 years received 0.025 mg/kg zoledronic acid (up to a maximum single dose of 0.35 mg) every 3 months and patients aged 3 to 17 years received 0.05 mg/kg zoledronic acid (up to a maximum single dose of 0.83 mg) every 3 months. An extension study was conducted in order to examine the long-term general and renal safety of once yearly or twice yearly zoledronic acid over the 12-month extension treatment period in children who had completed one year of treatment with either zoledronic acid or pamidronate in the core study.</p><p style="margin-left:3.6pt; margin-right:36.0pt">The primary endpoint of the study was the percent change from baseline in lumbar spine bone mineral density (BMD) after 12 months of treatment. Estimated treatment effects on BMD were similar, but the trial design was not sufficiently robust to establish non-inferior efficacy for zoledronic acid. In particular there was no clear evidence of efficacy on incidence of fracture or on pain. Fracture adverse events of long bones in the lower extremities were reported in approximately 24% (femur) and 14% (tibia) of zoledronic acid-treated patients vs 12% and 5% of pamidronate-treated patients with severeosteogenesis imperfecta, regardless of disease type and causality but overall incidence of fractures was comparable for the zoledronic acid and pamidronate-treated patients: 43% (32/74) vs 41% (31/76). Interpretation of the risk of fracture is confounded by the fact that fractures are common events in patients with severe osteogenesis imperfecta as part of the disease process.</p><p style="margin-left:3.6pt; margin-right:21.6pt; text-align:justify">The type of adverse reactions observed in this population were similar to those previously seen in adults with advanced malignancies involving the bone (see section 4.8). The adverse reactions ranked under headings of frequency, are presented in Table 6. The following conventional classification is used: very common (&ge;1/10), common (&ge;1/100, to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000, to &lt;1/1,000), very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><p style="margin-left:3.6pt; margin-right:1.8pt"><strong>Table 6: </strong>Adverse reactions observed in paediatric patients with severe osteogenesis imperfecta<sup>1</sup></p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="border-color:black; height:26.15pt; vertical-align:top; width:457.95pt"><p style="margin-left:3.6pt"><strong><em>Nervous system disorders</em></strong></p><p style="margin-left:90.0pt; margin-right:0cm">Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p></td></tr><tr><td style="border-color:black; height:25.95pt; vertical-align:top; width:457.95pt"><p style="margin-left:3.6pt"><strong><em>Cardiac disorders</em></strong></p><p style="margin-left:90.0pt; margin-right:0cm">Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tachycardia</p></td></tr><tr><td style="border-color:black; height:25.65pt; vertical-align:top; width:457.95pt"><p style="margin-left:3.6pt"><strong><em>Respiratory, thoracic and mediastinal disorders</em></strong></p><p style="margin-left:90.0pt; margin-right:0cm">Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nasopharyngitis</p></td></tr><tr><td style="border-color:black; height:39.15pt; vertical-align:top; width:457.95pt"><p style="margin-left:3.6pt"><strong><em>Gastrointestinal disorders</em></strong></p><p style="margin-left:90.0pt">Very common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting, nausea</p><p style="margin-left:90.0pt; margin-right:0cm">Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal pain</p></td></tr><tr><td style="border-color:black; height:38.4pt; vertical-align:top; width:457.95pt"><p style="margin-left:3.6pt"><strong><em>Musculoskeletal and connective tissue disorders</em></strong></p><p style="margin-left:234.0pt; margin-right:19.8pt; text-indent:-144.0pt">Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain in extremities, arthralgia, musculoskeletal pain</p></td></tr><tr><td style="border-color:black; height:39.1pt; vertical-align:top; width:457.95pt"><p style="margin-left:3.6pt"><strong><em>General disorders and administration site conditions</em></strong></p><p style="margin-left:90.0pt">Very common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pyrexia, fatigue</p><p style="margin-left:90.0pt; margin-right:0cm">Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute phase reaction, pain</p></td></tr><tr><td style="border-color:black; height:39.85pt; vertical-align:top; width:457.95pt"><p style="margin-left:3.6pt"><strong><em>Investigations</em></strong></p><p style="margin-left:90.0pt">Very common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypocalcaemia</p><p style="margin-left:90.0pt; margin-right:0cm">Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypophosphataemia</p></td></tr></tbody></table><p>&nbsp;</p><p style="margin-left:10.8pt; margin-right:25.2pt">1 Adverse events occurring with frequencies &lt; 5% were medically assessed and it was shown that these cases are consistent with the well established safety profile of Zoledronic acid as indicated in sections 4.1 and 4.2 (see section 4.8)</p><p style="margin-left:3.6pt; margin-right:14.4pt">In paediatric patients with severe osteogenesis imperfecta, zoledronic acid seems to be associated with more pronounced risks for acute phase reaction, hypocalcaemia and unexplained tachycardia, in comparison to pamidronate, but this difference declined after subsequent infusions.</p><p style="margin-left:3.6pt; margin-right:14.4pt; text-align:justify">The European Medicines Agency has waived the obligation to submit the results of studies with the reference medicinal product containing zoledronic acid in all subsets of the paediatric population in the treatment of tumour-induced hypercalcaemia and prevention of skeletal-related events in patients with advanced malignancies involving bone (see section 4.2 for information on paediatric use).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:3.6pt; margin-right:36.0pt">Single and multiple 5- and 15-minute infusions of 2, 4, 8 and 16 mg zoledronic acid in 64 patients with bone metastases yielded the following pharmacokinetic data, which were found to be dose independent.</p><p style="margin-left:7.2pt; margin-right:10.8pt">After initiating the infusion of zoledronic acid, the plasma concentrations of zoledronic acid rapidly increased, achieving their peak at the end of the infusion period, followed by a rapid decline to &lt; 10% of peak after 4 hours and &lt; 1% of peak after 24 hours, with a subsequent prolonged period of very low concentrations not exceeding 0.1% of peak prior to the second infusion of zoledronic acid on day 28.</p><p style="margin-left:7.2pt; margin-right:14.4pt">Intravenously administered zoledronic acid is eliminated by a triphasic process: rapid biphasic disappearance from the systemic circulation, with half-lives of <sub>t1/2&alpha;</sub> 0.24 and <sub>t1/2&beta;</sub> 1.87 hours, followed by a long elimination phase with a terminal elimination half-life of <sub>t1/2&gamma;</sub> 146 hours. There was no accumulation of zoledronic acid in plasma after multiple doses given every 28 days. Zoledronic acid is not metabolised and is excreted unchanged via the kidney. Over the first 24 hours, 39 &plusmn; 16% of the administered dose is recovered in the urine, while the remainder is principally bound to bone tissue. From the bone tissue it is released very slowly back into the systemic circulation and eliminated via the kidney. The total body clearance is 5.04 &plusmn; 2.5 l/h, independent of dose, and unaffected by gender, age, race, and body weight. Increasing the infusion time from 5 to 15 minutes caused a 30% decrease in zoledronic acid concentration at the end of the infusion, but had no effect on the area under the plasma concentration versus time curve. An infusion time 20 minutes provides acceptable peak plasma concentrations without increased risk for renal toxicity.</p><p style="margin-left:7.2pt; margin-right:18.0pt">The interpatient variability in pharmacokinetic parameters for zoledronic acid was high, as seen with other bisphosphonates.</p><p style="margin-left:7.2pt; margin-right:21.6pt">No pharmacokinetic data for zoledronic acid are available in patients with hypercalcaemia or in patients with hepatic insufficiency. Zoledronic acid does not inhibit human P450 enzymes <em>in vitro, </em>shows no biotransformation and in animal studies &lt; 3% of the administered dose was recovered in the faeces, suggesting no relevant role of liver function in the pharmacokinetics of zoledronic acid.</p><p style="margin-left:7.2pt; margin-right:7.2pt">The renal clearance of zoledronic acid was correlated with creatinine clearance, renal clearance representing 75 &plusmn; 33% of the creatinine clearance, which showed a mean of 84 &plusmn; 29 ml/min (range 22 to 143 ml/min) in the 64 cancer patients studied. Population analysis showed that for a patient with creatinine clearance of 20 ml/min (severe renal impairment), or 50 ml/min (moderate impairment), the corresponding predicted clearance of zoledronic acid would be 37% or 72%, respectively, of that of a patient showing creatinine clearance of 84 ml/min. Only limited pharmacokinetic data are available in patients with severe renal insufficiency (creatinine clearance &lt; 30 ml/min).</p><p style="margin-left:7.2pt; margin-right:18.0pt">Zoledronic acid shows no affinity for the cellular components of blood and plasma protein binding is low (approximately 56%) and independent of the concentration of zoledronic acid.</p><p style="margin-left:7.2pt; margin-right:1.8pt; text-align:justify"><u>Special populations </u></p><p style="margin-left:7.2pt; margin-right:1.8pt; text-align:justify"><em>Paediatric patients</em></p><p style="margin-left:7.2pt; margin-right:7.2pt; text-align:justify">Limited pharmacokinetic data in children with severe osteogenesis imperfecta suggest that zoledronic acid pharmacokinetics in children aged 3 to 17 years are similar to those in adults at a similar mg/kg dose level. Age, body weight, gender and creatinine clearance appear to have no effect on zoledronic acid systemic exposure.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:7.2pt; margin-right:1.8pt"><u>Acute toxicity</u></p><p style="margin-left:7.2pt; margin-right:1.8pt">The highest non-lethal single intravenous dose was 10 mg/kg bodyweight in mice and 0.6 mg/kg in</p><p style="margin-left:7.2pt; margin-right:1.8pt">rats.</p><p style="margin-left:7.2pt; margin-right:1.8pt"><u>Subchronic and chronic toxicity</u></p><p style="margin-left:7.2pt; margin-right:10.8pt">Zoledronic acid was well tolerated when administered subcutaneously to rats and intravenously to dogs at doses up to 0.02 mg/kg daily for 4 weeks. Administration of 0.001 mg/kg/day subcutaneously in rats and 0.005 mg/kg intravenously once every 2-3 days in dogs for up to 52 weeks was also well tolerated.</p><p style="margin-left:7.2pt; margin-right:54.0pt">The most frequent finding in repeat-dose studies consisted of increased primary spongiosa in the metaphyses of long bones in growing animals at nearly all doses, a finding that reflected the compound&#39;s pharmacological antiresorptive activity.</p><p style="margin-left:7.2pt; margin-right:25.2pt">The safety margins relative to renal effects were narrow in the long-term repeat-dose parenteral animal studies but the cumulative no adverse event levels (NOAELs) in the single dose (1.6 mg/kg) and multiple dose studies of up to one month (0.06-0.6 mg/kg/day) did not indicate renal effects at doses equivalent to or exceeding the highest intended human therapeutic dose. Longer-term repeat administration at doses bracketing the highest intended human therapeutic dose of zoledronic acid produced toxicological effects in other organs, including the gastrointestinal tract, liver, spleen and lungs, and at intravenous injection sites.</p><p style="margin-left:7.2pt; margin-right:1.8pt"><u>Reproduction toxicity</u></p><p style="margin-left:7.2pt; margin-right:32.4pt">Zoledronic acid was teratogenic in the rat at subcutaneous doses &gt; 0.2 mg/kg. Although no teratogenicity or foetotoxicity was observed in the rabbit, maternal toxicity was found. Dystocia was observed at the lowest dose (0.01 mg/kg bodyweight) tested in the rat.</p><p style="margin-left:7.2pt; margin-right:1.8pt"><u>Mutagenicity and carcinogenic potential</u></p><p style="margin-left:7.2pt; margin-right:1.8pt">Zoledronic acid was not mutagenic in the mutagenicity tests performed and carcinogenicity testing did</p><p style="margin-left:7.2pt; margin-right:1.8pt">not provide any evidence of carcinogenic potential.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:7.2pt; margin-right:1.8pt">Mannitol</p><p style="margin-left:7.2pt; margin-right:1.8pt">Sodium citrate</p><p style="margin-left:7.2pt; margin-right:1.8pt">Water for injections</p><p style="margin-left:7.2pt; margin-right:54.0pt">This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. it is essentially &ldquo;sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:7.2pt; margin-right:46.8pt">To avoid potential incompatibilities, Zoledronic acid concentrate is to be diluted with 0.9% w/v sodium chloride solution or 5% w/v glucose solution.</p><p style="margin-left:7.2pt; margin-right:50.4pt">Zoledronic acid concentrate must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer&#39;s solution, and should be administered as a single intravenous solution in a separate infusion line.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                30 months.
After dilution: Chemical and physical in-use stability has been demonstrated for 24 hours at 2°C-8ºC.From a microbiological point of view, the diluted solution for infusion should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C – 8°C. The refrigerated solution should 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:7.2pt">This medicinal product does not require any special storage<br />condition. For storage conditions of the diluted medicinal<br />product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:7.2pt; margin-right:10.8pt">Plastic vial made of colourless polypropylene closed with bromobutyl rubber stopper and aluminium cap with plastic flip-off component.</p><p style="margin-left:7.2pt">Packs containing 1, 4 or 10 vials.<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:7.2pt; margin-right:7.2pt">Prior to administration, 5.0 ml concentrate from one vial or the volume of the concentrate withdrawn as required must be further diluted with 100 ml of calcium-free infusion solution (0.9% w/v sodium chloride solution or 5% w/v glucose solution).</p><p style="margin-left:7.2pt; margin-right:7.2pt">Studies with glass bottles, as well as several containers types made from polyvinylchloride, polyethylene and polypropylene (prefilled with 0.9% w/v sodium chloride solution or 5% w/v glucose solution), showed no incompatibility with Zoledronic acid Fresenius Kabi.</p><p style="margin-left:7.2pt; margin-right:61.2pt">Additional information on handling of Zoledronic acid Fresenius Kabi, including guidance on preparation of reduced doses, is provided in section 4.2.</p><p style="margin-left:7.2pt; margin-right:32.4pt">Aseptic techniques must be followed during the preparation of the infusion. For single use only. Only clear solution free from particles and discolouration should be used.</p><p style="margin-left:7.2pt; margin-right:28.8pt">Healthcare professionals are advised not to dispose of unused Zoledronic acid Fresenius Kabi via the domestic sewage system.</p><p style="margin-left:7.2pt; margin-right:39.6pt">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Fresenius Kabi Austria GmbH
Hafnerstaße 36
8055 Graz
Austria
And
Fresenius Kabi Deutschland GmbH
D-61346 Bad Homburg v.d.H, Germany

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                06/2015
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>